Trends in end-of-life (EOL) systemic oncologic treatment in contemporary clinical practice: insights from real-world data Published September 2021 Citation Canavan, M, Wang, X, Ascha, MS, Miksad, RA, Showalter, TN, Calip, GS, Gross, CP. . ASCO Quality Care Symposium. . https://ascopubs.org/doi/abs/10.1200/JCO.2020.39.28_suppl.253 Authors:Canavan, M, Wang, X, Ascha, MS, Miksad, RA, Showalter, TN, Calip, GS, Gross, CP Sources:ASCO Quality Care Symposium Share Posted inPublicationsTreatment patterns More publicationsASCO GUFebruary 2026Real-world (rw) first-line (1L) treatment (tx) patterns and overall survival (rwOS) in patients (pts) with locally advanced/metastatic urothelial carcinoma (la/mUC) with frailty or comorbiditiesGrande E, Bamias A, Wit, R, et al. Publication summaryPublicationsTreatment patternsUrothelial cell carcinomaASCO GUFebruary 2026Real-world neoadjuvant therapy utilization and outcomes in patients with muscle-invasive bladder cancer ineligible for cisplatin treatmentPatel K, Zhao D, Hankinson E, et al.Publication summaryPublicationsTreatment patternsASCO GUFebruary 2026Beyond BRCA: Real-world outcomes with poly(ADP-ribose) polymerase inhibitors among patients with metastatic castration-resistant prostate cancer and homologous recombination repair mutationsHankinson E, Kerr B, Ward P, et al. Publication summaryPublicationsTreatment patternsProstate cancer